trial

Safety Study of ORG 34517 for Major Depression With Psychotic Features

NCTId NCT00226278
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 25 (estimated)
Sponsored by Weill Medical College of Cornell University
Primary completion 2005-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
25 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2004-09
Primary completion
2005-11
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Org 34517

Sponsors

Weill Medical College of Cornell UniversityLead Sponsor

Investigators

1
James H Kocsis, MDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Safety Study of ORG 34517 for Major Depression With Psychotic Features — primary completion2005-11

Facts & assertions

4 sourced
Enrollment
25
Phase
PHASE2
Primary Completion Date
2005-11
Status
COMPLETED
relationships
The graph out of here
drug
Org 34517
drug
lead_sponsor
Weill Medical College of Cornell University
company
indication
Major Depressive Disorder
indication
Depressive Disorder, Major
indication
Psychotic Disorders
indication
investigator
James H Kocsis, MD
person